Combination studies with gemcitabine in the treatment of non-small-cell lung cancer.

Phase II studies have confirmed gemcitabine (GEMZAR) to be an active single agent in treating non-small-cell lung cancer (NSCLC), with response rates averaging 21%. Toxicity, including myelosuppression, is mild, making gemcitabine an attractive agent to consider in combination regimens. Most experie...

Descripción completa

Detalles Bibliográficos
Autor principal: Steward, W. P.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062800/
https://www.ncbi.nlm.nih.gov/pubmed/9717986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062800/
https://www.ncbi.nlm.nih.gov/pubmed/9717986

Ejemplares similares